Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for From Bio Co., Ltd. (377220:KRX), powered by AI.
From Bio Co., Ltd. is currently trading at ₩773. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for From Bio Co., Ltd. on Alpha Lenz.
From Bio Co., Ltd.'s P/E ratio is -1.0.
“From Bio Co., Ltd. trades at a P/E of -1.0 (undervalued) with modest ROE of -57.4%.”
Ask for details →From Bio Co., Ltd. is a biotechnology company engaged in the development and commercialization of innovative healthcare solutions. Primarily focusing on the pharmaceutical and nutraceutical segments, From Bio leverages advanced biotechnological research to address a wide range of health conditions. The company's core product offerings include dietary supplements, functional foods, and health aids that aim to promote wellness and preventive healthcare. By integrating natural ingredients with cutting-edge biotechnology, From Bio Co., Ltd. addresses the growing consumer demand for scientifically supported health products. The firm operates in both domestic and international markets, serving diverse sectors such as personalized nutrition, lifestyle enhancement, and over-the-counter healthcare. With its commitment to quality and innovation, From Bio plays a significant role in the biopharmaceutical industry, contributing to the development of products that support sustainable health solutions for a global audience. By continuing to focus on research and expanding its portfolio, the company strengthens its market presence and fosters advancements in the biotech sector.
“From Bio Co., Ltd. trades at a P/E of -1.0 (undervalued) with modest ROE of -57.4%.”
Ask for details →From Bio Co., Ltd. (ticker: 377220) is a company listed on KRX in the Consumer Defensive sector (Packaged Foods). Market cap is $21.9B.
The current price is ₩773 with a P/E ratio of -0.97x and P/B of 0.78x.
ROE is -57.38% and operating margin is -25.78%. Annual revenue is $72.2B.